Optimal Management of RTI – Intriguing New Results in ABECOPD in Asia
References
| 1. | Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41: 2256-60. |
| 2. | Chien SC, Wong FA, Fowler CL, Callery-D’Amico SV, Williams RR, Nayak R, Chow AT. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 885-8. |
| 3. | Zhang J, Xu JF, Liu YB, Xiao ZK, Huang JA, Si B, Sun SH, Xia QM, Wu XJ, Cao GY, Shi YG, Zhang YY. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Chemother 2009; 15: 293 -300. |
| 4. | Cazzola M, Matera MG, Donnarumma G, Tufano MA, Sanduzzi A, Marchetti F, Blasi F. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. Chest 2005; 128: 2093-8. |
| 5. | Garrison MW. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2006; 54: 51 -6. |
| 6. | Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752-60. |
| 7. | File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 2004; 20: 1473-81. |
| 8. | Shorr AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥ 65 years with community-acquired pneumonia. Clin Ther 2005; 27: 1251-9. |
| 9. | Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006; 100: 2129- 36. |
| 10. | Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008; 68: 535-65. |
| 11. | Wasserfallen JB, Erard V, Cometta A, Calandra T, Lamy O. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J 2004; 24: 644-8. |
| 12. | Yamaguchi H, Kawai H, Matsumoto T, Yokoyama H, Nakayasu T, Komiya M, Shimada J. Post-marketing surveillance of the safety of levofloxacin in Japan. Chemotherapy 2007; 53: 85- 103. |
| 13. | Khashab MM, Xiang J, Kahn JB. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin 2006; 22: 1997-2006. |
| 14. | Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196 -204. |
| 15. | Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Executive summary. Updated 2009. Available from: URL: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2180. Accessed July 2010. |
| 16. | Ip M, Ling T, Hui DS, Chang SC, Yoo CG, Kim EC, Visit U, Somkid M, Razak M, Azmi M, Roa C, Mendoza M, Priyanti S, Pratiwi S, Hadiarto M. Pathogens and in vitro antibiotic sensitivities in Asian ABECOPD population (Part 2: From Seven Countries) (poster); 4th Asia-Pacific Advisory Board (APAB) on Respiratory Tract Infection. Seoul, Korea, 2009. |
| 17. | Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 7th ed. Approved standard CLSI document M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute, 2006. |
| 18. | Anzueto A, Miravitlles M. Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respir Med 2010 Jun 24; [Epub ahead of print]. |
 |
 |
LATEST TOPICS
RELATED ARTICLES
